Galmed Pharmaceuticals Ltd (FRA:GPH)
€ 2.736 0 (0%) Market Cap: 4.81 Mil Enterprise Value: -7.27 Mil PE Ratio: 0 PB Ratio: 0.26 GF Score: 35/100

Galmed Pharmaceuticals Ltd KOL Symposium and Pipeline Update Transcript

Jan 26, 2021 / 04:00PM GMT
Release Date Price: €550.8 (+2.68%)
Sara Parigian
LifeSci Advisors, LLC - VP of KOL Strategy & Management

Good afternoon and welcome to the Galmed KOL Symposium and Pipeline Update. (Operator Instructions) As a reminder, this webinar is being recorded, and a replay of the event and the investor deck will be made available on the Galmed website following the conclusion of the event.

I would now like to turn the call over to your host, Allen Baharaff, President and Chief Executive Officer of Galmed Pharmaceuticals. Please go ahead, Allen.

Allen Baharaff
Galmed Pharmaceuticals Ltd. - Co-Founder, President, CEO & Chairman

Thank you, Sara. Good afternoon and welcome to our KOL symposium.

Next slide, please. This is our safe harbor and disclaimer statement.

Next slide, please. Special welcome to our KOLs, Professor Arun Sanyal, Professor of Medicine and Chairman to the Gastroenterology division, the Virginia Commonwealth University and our ARMOR Phase III core principal investigator; Professor Shomron Ben-Horin, Chief and Gastro -- Chief of the Gastroenterology

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot